Taking advantage of the discoveries and therapeutics designed to attenuate tau dysfunction in AD (101), as a significant number of preclinical studies and clinical trials have already been initiated, may indeed prove to be useful in HD as well. The gene discussed is MAPT; the disease is Alzheimer disease.